Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP3 | P08254 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL273144 | 0.82 | MMP1 (0.47) | MMP1MMP3MMP8HTTCA12 | |
| SCHEMBL975100 | 0.77 | MMP1 (0.42) | MMP1MMP3MMP8HTTCA12 | |
| SCHEMBL9346545 | 0.76 | MMP1 (0.40) | MMP1MMP3MMP8HTTCA12 | |
| SCHEMBL32685957 | 0.73 | MMP1 (0.38) | MMP1MMP3MMP8HTTCA12 | |
| SCHEMBL5691755 | 0.73 | ANPEP (0.44) | MMP1MMP3MMP8HTTCA12 | |
| SCHEMBL3363445 | 0.71 | ALDH1A1 (0.38) | MMP1MMP3MMP8HTTSMN1; SMN2 | |
| SCHEMBL329843 | 0.67 | MMP1 (0.50) | MMP1MMP3MMP8CA12CA1 | |
| SCHEMBL2974382 | 0.67 | MMP1 (0.50) | MMP1MMP3MMP8CA12CA1 | |
| SCHEMBL8009456 | 0.66 | — | — | |
| Hydrochloric Acid SCHEMBL11081547 | 0.65 | MMP1 (0.48) | MMP1MMP3MMP8CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 331 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3850099-B1 | MICRORNA INHIBITORS FOR USE IN TREATING METABOLIC DISEASES | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH (DE) | 2025-09-03 | — | — | EP | claimed |
| US-20240060068-A1 | POLY-MORPHOLINO OLIGONUCLEOTIDE GAPMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-02-22 | — | — | US | claimed |
| CN-117120456-A | Poly-morpholino oligonucleotide gap body | 卫材R&D管理有限公司 | 2023-11-24 | — | — | CN | claimed |
| EP-4259798-A1 | POLY-MORPHOLINO OLIGONUCLEOTIDE GAPMERS | Eisai R&D Management Co., Ltd. (JP) | 2023-10-18 | — | — | EP | claimed |
| WO-2022125987-A1 | POLY-MORPHOLINO OLIGONUCLEOTIDE GAPMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-16 | — | — | WO | claimed |
| US-12595486-B2 | Aptamers for personal health care applications | THE PROCTER & GAMBLE COMPANY (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260085087-A1 | CHEMICAL COMPOUND COMPRISING A TRIAZINE GROUP AND METHOD FOR PRODUCING SAME | KUPRYUSHKIN MAXIM SERGEEVICH (RU) | 2026-03-26 | — | — | US | disclosed |
| US-12584137-B2 | Aptamers for personal health care applications | THE PROCTER & GAMBLE COMPANY (US) | 2026-03-24 | — | — | US | disclosed |
| US-12584136-B2 | Aptamers for personal health care applications | THE PROCTER & GAMBLE COMPANY (US) | 2026-03-24 | — | — | US | disclosed |
| US-12584135-B2 | Aptamers for personal health care applications | THE PROCTER & GAMBLE COMPANY (US) | 2026-03-24 | — | — | US | disclosed |
| US-12359205-B2 | Aptamers for personal health care applications | THE PROCTER & GAMBLE COMPANY (US) | 2025-07-15 | — | — | US | disclosed |
| EP-3664776-B1 | APTAMERS FOR CONSUMER PRODUCT COMPOSITIONS | PROCTER & GAMBLE (US) | 2025-05-14 | — | — | EP | disclosed |
| US-6743905-B2 | BIOPOLYMER FOR USE IN THE DETECTION OF PREERENTIAL SEQUENCES IN SAMPLE | APPLERA CORPORATION | 2004-06-01 | — | — | US | disclosed |
| EP-1334110-A2 | METHODS FOR ISOLATING ONE STRAND OF A DOUBLE-STRANDED NUCLEIC ACID | Applera Corporation (US) | 2003-08-13 | — | — | EP | disclosed |
| US-20030148277-A1 | Methods for isolating one strand of a double-stranded nucleic acid | APPLIED BIOSYSTEMS, LLC | 2003-08-07 | — | — | US | disclosed |
| US-20020182602-A1 | Mobility-modified nucleobase polymers and methods of using same | APPLIED BIOSYSTEMS, INC. | 2002-12-05 | — | — | US | disclosed |
| WO-2002010182-A2 | METHODS FOR ISOLATING ONE STRAND OF A DOUBLE-STRANDED NUCLEIC ACID | APPLERA CORPORATION (US) | 2002-02-07 | — | — | WO | disclosed |
| EP-0605582-A1 | PHOSPHORAMIDATE ANALOGS OF 5-FLUORO-2'-DEOXYURIDINE | THE UNIVERSITY OF ROCHESTER (US) | 1994-07-13 | — | — | EP | disclosed |
| US-5233031-A | Antitumor, anticarcinogenic agents | UNIVERSITY OF ROCHESTER (US) | 1993-08-03 | — | — | US | disclosed |
| WO-1993006120-A1 | PHOSPHORAMIDATE ANALOGS OF 5-FLUORO-2'-DEOXYURIDINE | UNIVERSITY OF ROCHESTER (US) | 1993-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085087-A1 | CHEMICAL COMPOUND COMPRISING A TRIAZINE GROUP AND METHOD FOR PRODUCING SAME | NSUN2, POLM, SSU72 | MMP1 4721/4885MMP3 4235/4885MMP8 3882/4885 |
| US-20020182602-A1 | Mobility-modified nucleobase polymers and methods of using same | PCNA, PNKP, SAMHD1 | MMP1 1888/4885MMP3 1693/4885MMP8 768/4885 |
| US-12584136-B2 | Aptamers for personal health care applications | HAVCR2, LDLR, ICAM1 | MMP1 4300/4885MMP3 3143/4885MMP8 3667/4885 |
| US-20240060068-A1 | POLY-MORPHOLINO OLIGONUCLEOTIDE GAPMERS | RNMT, GAP43, MCTS1 | MMP1 3535/4885MMP3 3632/4885MMP8 3892/4885 |
| US-12584135-B2 | Aptamers for personal health care applications | ICAM1, VCAM1, EPCAM | MMP1 3579/4885MMP3 2294/4885MMP8 3099/4885 |
| US-12595486-B2 | Aptamers for personal health care applications | HAVCR2, EPCAM, ICAM1 | MMP1 4358/4885MMP3 2295/4885MMP8 3097/4885 |
| US-12584137-B2 | Aptamers for personal health care applications | HAVCR2, LDLR, ICAM1 | MMP1 4298/4885MMP3 2224/4885MMP8 2803/4885 |
| US-20030148277-A1 | Methods for isolating one strand of a double-stranded nucleic acid | POLRMT, POLN, ADAR | MMP1 3912/4885MMP3 1840/4885MMP8 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.